Risk Factors—Risks Related to Doing Business in China—If we are classified as a mainland China resident enterprise for mainland China income tax purposes, such classification could result in unfavorable tax consequences to us and our non-mainland China shareholders and ADS holders.” 115 Table of Contents The PRC Enterprise Income Tax Law also imposes a withholding income tax of 10% on dividends distributed by a foreign-invested enterprise to its immediate holding company outside of China, if such immediate holding company is considered as a non-resident enterprise without any establishment or place within China or if the received dividends have no connection with the establishment or place of such immediate holding company within China, unless such immediate holding company’s jurisdiction of incorporation has a tax treaty with China that provides for a different withholding arrangement.
Risk Factors—Risks Related to Doing Business in China—If we are classified as a mainland China resident enterprise for mainland China income tax purposes, such classification could result in unfavorable tax consequences to us and our non-mainland China shareholders and ADS holders.” 110 Table of Contents The PRC Enterprise Income Tax Law also imposes a withholding income tax of 10% on dividends distributed by a foreign-invested enterprise to its immediate holding company outside of China, if such immediate holding company is considered as a non-resident enterprise without any establishment or place within China or if the received dividends have no connection with the establishment or place of such immediate holding company within China, unless such immediate holding company’s jurisdiction of incorporation has a tax treaty with China that provides for a different withholding arrangement.
Our research and development expenses mainly consist of (i) payroll and related expenses for employees involved in platform and new function development and significant improvement, and (ii) charges for the usage of the server and cloud service incurred to support research, design, and development activities by research and development personnel, as well as (iii) expenses of facilities and equipment, such as depreciation expenses, rental and others. 114 Table of Contents Taxation Cayman Islands The Cayman Islands currently levies no taxes on corporations based upon profits, income, gains or appreciations.
Our research and development expenses mainly consist of (i) payroll and related expenses for employees involved in platform and new function development and significant improvement, and (ii) charges for the usage of the server and cloud service incurred to support research, design, and development activities by research and development personnel, as well as (iii) expenses of facilities and equipment, such as depreciation expenses, rental and others. 109 Table of Contents Taxation Cayman Islands The Cayman Islands currently levies no taxes on corporations based upon profits, income, gains or appreciations.
If it is determined that we are unable to realize a deferred tax asset, we would adjust the valuation allowance in the period in which such a determination is made, with a corresponding decrease to earnings. 120 Table of Contents Recent Accounting Pronouncements A list of recently issued accounting pronouncements that are relevant to us is included in Note 2 “Recent accounting pronouncements” to our audited consolidated financial statements included elsewhere in this annual report.
If it is determined that we are unable to realize a deferred tax asset, we would adjust the valuation allowance in the period in which such a determination is made, with a corresponding decrease to earnings. 115 Table of Contents Recent Accounting Pronouncements A list of recently issued accounting pronouncements that are relevant to us is included in Note 2 “Recent accounting pronouncements” to our audited consolidated financial statements included elsewhere in this annual report.
E. Critical Accounting Estimates For our critical accounting estimates, see “Item 5. Operating and Financial Review and Prospects—Critical Accounting Estimates.” F. Safe Harbor See “Forward-Looking Information” on page 2 of this annual report.
Critical Accounting Estimates For our critical accounting estimates, see “Item 5. Operating and Financial Review and Prospects—Critical Accounting Estimates.” F. Safe Harbor See “Forward-Looking Information” on page 2 of this annual report.
Our prepaid expense and other assets represent primarily (i) the fund receivable from external payment service providers through which we collect and transfer insurance premiums to insurance carriers, and donors’ donation received by our external payment service provider prior to those being transferred to custodian bank, and (ii) the advances to suppliers, such as the prepayments to third-party traffic channels.
Our prepaid expense and other assets represent primarily (i) prepayments and deposits, (ii) the fund receivable from external payment service providers through which we collect and transfer insurance premiums to insurance carriers, and donors’ donation received by our external payment service provider prior to those being transferred to custodian bank, and (iii) the advances to suppliers, such as the prepayments to third-party traffic channels.
The presumption may be overcome if we have sufficient evidence to demonstrate that the undistributed dividends will be re-invested and the remittance of the dividends will be postponed indefinitely. We did not record any deferred tax liabilities for dividend withholding tax, as we have no retained earnings for the years ended December 31, 2021, 2022 and 2023. See “Item 3.
The presumption may be overcome if we have sufficient evidence to demonstrate that the undistributed dividends will be re-invested and the remittance of the dividends will be postponed indefinitely. We did not record any deferred tax liabilities for dividend withholding tax, as we have no retained earnings for the years ended December 31, 2022, 2023 and 2024. See “Item 3.
We believe FYP is a strong indicator of brokerage income because it better demonstrates the brokerage income potential we may generate for an insurance policy.
We believe FYP is a strong indicator of brokerage income because it better demonstrates the brokerage income we may generate for an insurance policy.
Other than as discussed above, we did not have any significant capital and other commitments, long-term obligations or guarantees as of December 31, 2023. Holding Company Structure Waterdrop Inc. is a holding company with no material operations of its own. We conduct our operations primarily through our WFOE and the VIEs.
Other than as discussed above, we did not have any significant capital and other commitments, long-term obligations or guarantees as of December 31, 2024. Holding Company Structure Waterdrop Inc. is a holding company with no material operations of its own. We conduct our operations primarily through our WFOE and the VIEs.
We have also been endeavoring to optimize our marketing strategies by adjusting our selling and marketing expenses and allocation of marketing resources. For instance, we moderately increased our investment in third-party traffic channels to promote certain new products in 2023.
We have also been endeavoring to optimize our marketing strategies by adjusting our selling and marketing expenses and allocation of marketing resources. For instance, we moderately increased our investment in third-party traffic channels to promote certain new products in 2024.
While our business is influenced by general factors affecting our industry, our results of operations are more directly affected by company-specific factors, including the following major ones: 110 Table of Contents Expansion and retention of consumer base Brokerage income earned from insurance carriers through our insurance marketplace is the main source of our revenue, which is significantly affected by the number of insurance consumers on the Waterdrop Insurance Marketplace and Shenlanbao Insurance Marketplace.
While our business is influenced by general factors affecting our industry, our results of operations are more directly affected by company-specific factors, including the following major ones: Expansion and retention of consumer base Brokerage income earned from insurance carriers through our insurance marketplace is the main source of our revenue, which is significantly affected by the number of insurance consumers on the Waterdrop Insurance Marketplace and Shenlanbao Insurance Marketplace.
The net operating revenue from other business increased by 46.4% from RMB86.8 million in 2022 to RMB127.1 million (US$17.9 million) in 2023, which was mainly due to the 69.0% increase of digital clinical trial solution income as a result of the increase in the number of patients successfully enrolled from 2,846 in 2022 to more than 3,300 patients in 2023.
The net operating revenue from other business increased by 46.4% from RMB86.8 million in 2022 to RMB127.1 million in 2023, which was mainly due to the 69.0% increase of digital clinical trial solution income as a result of the increase in the number of patients successfully enrolled from 2,846 in 2022 to more than 3,300 patients in 2023.
As of December 31, 2023, as our WFOE, almost all other subsidiaries in mainland China, the VIEs and the subsidiaries of the VIEs are in an accumulated loss position, no statutory reserve was appropriated.
As of December 31, 2024, as our WFOE, almost all other subsidiaries in mainland China, the VIEs and the subsidiaries of the VIEs are in an accumulated loss position, no statutory reserve was appropriated.
The net operating revenue from crowdfunding business increased by 4.4% from RMB155.8 million in 2022 to RMB162.7 million (US$22.9 million) in 2023, which was mainly because we started to charge crowdfunding service fees in April 2022 and have generated revenue from crowdfunding service fees since then.
The net operating revenue from crowdfunding business increased by 4.4% from RMB155.8 million in 2022 to RMB162.7 million in 2023, which was mainly because we started to charge crowdfunding service fees in April 2022 and have generated revenue from crowdfunding service fees since then.
Our WFOE has not paid dividends and will not be able to pay dividends until it generates accumulated profits and meets the requirements for statutory reserve fund. 124 Table of Contents C. Research and Development See “Item 4. Information on the Company—B. Business Overview—Technology and Infrastructure” and “Item 4. Information on the Company—B. Business Overview—Intellectual Property.” D.
Our WFOE has not paid dividends and will not be able to pay dividends until it generates accumulated profits and meets the requirements for statutory reserve fund. C. Research and Development See “Item 4. Information on the Company—B. Business Overview— Technology and Infrastructure” and “Item 4. Information on the Company—B. Business Overview—Intellectual Property.” D.
Research and development expenses Our research and development expenses increased by 2.7% from RMB291.3 million in 2022 to RMB299.1 million (US$42.1 million) in 2023.
Research and development expenses Our research and development expenses increased by 2.7% from RMB291.3 million in 2022 to RMB299.1 million in 2023.
Trend Information Other than as disclosed elsewhere in this annual report, we are not aware of any trends, uncertainties, demands, commitments or events for the period since January 1, 2024 that are reasonably likely to have a material effect on our revenues, income, profitability, liquidity or capital resources, or that would cause the disclosed financial information to be not necessarily indicative of future operating results or financial conditions.
Trend Information Other than as disclosed elsewhere in this annual report, we are not aware of any trends, uncertainties, demands, commitments or events for the period since January 1, 2025 that are reasonably likely to have a material effect on our revenues, income, profitability, liquidity or capital resources, or that would cause the disclosed financial information to be not necessarily indicative of future operating results or financial conditions. 119 Table of Contents E.
Investing activities Net cash used in investing activities in 2023 was RMB1,173.0 million (US$165.2 million), consisting primarily of net cash paid for acquisitions of subsidiaries, and net cash used in purchase of short-term and long-term investment products.
Net cash used in investing activities in 2023 was RMB1,173.0 million, consisting primarily of net cash paid for acquisitions of subsidiaries, and net cash used in purchase of short-term and long-term investment products.
Starting from the second quarter of 2023, our chief operating decision makers have been managing the business through three operating segments, and assessing the performance and allocating resources under the new operating segment structure.
Starting from the second quarter of 2023, our chief operating decision makers have been managing the business, assessing the performance and allocating resources under the new operating segment structure.
In addition, in terms of the technical support service, we primarily provide technical services to certain insurance brokerage or agency companies through our CRM system. We also provide marketing services to certain companies on our various website channels and apps. In addition, we provide risk management services to certain insurance companies.
In addition, in terms of the technical support service, we primarily provide technical services to certain insurance brokerage or agency companies through our CRM system. We also provide marketing services to certain companies on our various website channels and apps. In addition, we provide risk management services to certain insurance companies. 108 Table of Contents Crowdfunding.
The increase was primarily due to the consolidation of the financial results of Shenlanbao, which incurred research and development expenses of RMB12.0 million (US$1.7 million), partially offset by a decrease of RMB3.4 million (US$0.5 million) in research and development personnel costs and share-based compensation expenses.
The increase was primarily due to the consolidation of the financial results of Shenlanbao, which incurred research and development expenses of RMB12.0 million, partially offset by a decrease of RMB3.4 million in research and development personnel costs and share-based compensation expenses.
Information on the Company—C. Organizational Structure.” For restrictions and limitations on liquidity and capital resources as a result of our corporate structure, see “—Holding Company Structure.” Substantially all of our operating revenue has been, and we expect that it is likely to continue to be, in the form of Renminbi.
See “Item 4. Information on the Company—C. Organizational Structure.” For restrictions and limitations on liquidity and capital resources as a result of our corporate structure, see “—Holding Company Structure.” The majority of our operating revenue has been, and we expect that it is likely to continue to be, in the form of Renminbi.
The difference between the net profit of RMB163.7 million (US$23.1 million) and positive operating cash flow of RMB406.5 million (US$57.3 million) was certain adjustment of non-cash expenses items, such as share-based compensation expense of RMB133.9 million (US$18.9 million) and depreciation of property, equipment and software of RMB13.4 million (US$1.9 million), and changes in working capital accounts, which mainly include (i) RMB149.9 million (US$21.1 million) decrease in prepaid expense and other assets, and (ii) RMB75.3 million (US$10.6 million) increase in insurance premium payables, partially offset by (i) RMB43.5 million (US$6.1 million) decrease in accrued expenses and other current liabilities, and (ii) RMB99.9 million (US$14.1 million) increase in contract assets, and (iii) RMB36.7 million (US$5.2 million) increase in right of use assets, net.
The difference between the net profit of RMB163.7 million and positive operating cash flow of RMB406.5 million was certain adjustment of non-cash expenses items, such as share-based compensation expense of RMB133.9 million and depreciation of property, equipment and software of RMB13.4 million, and changes in working capital accounts, which mainly include (i) RMB149.9 million decrease in prepaid expense and other assets, and (ii) RMB75.3 million increase in insurance premium payables, partially offset by (i) RMB43.5 million decrease in accrued expenses and other current liabilities, and (ii) RMB99.9 million increase in contract assets, and (iii) RMB36.7 million increase in right of use assets, net.
The net operating revenue from insurance related business decreased by 8.5% from RMB2,559.2 million in 2022 to RMB2,340.9 million (US$329.7 million) in 2023, which was mainly due to the net impact of the decrease of the short-term insurance brokerage income by 15.2% from RMB1,628.9 million in 2022 to RMB1,381.9 million (US$194.6 million) in 2023, partially offset by the increase of the long-term insurance brokerage income by 15.2% from RMB714.4 million in 2022 to RMB823.3 million (US$116.0 million) in 2023.
The net operating revenue from insurance related business decreased by 8.5% from RMB2,559.2 million in 2022 to RMB2,340.9 million in 2023, which was mainly due to the net impact of the decrease of the short-term insurance brokerage income by 15.2% from RMB1,628.9 million in 2022 to RMB1,381.9 million in 2023, partially offset by the increase of the long-term insurance brokerage income by 15.2% from RMB714.4 million in 2022 to RMB823.3 million in 2023.
We will continue to make capital expenditures to meet our business growth. Our operating lease commitments consist of the commitments under the lease agreements for our office premises. Contractual obligation as of December 31, 2023 for our operating lease commitments amounted to RMB60.2 million (US$8.5 million).
We will continue to make capital expenditures to meet our business growth. Our operating lease commitments consist of the commitments under the lease agreements for our office premises. Contractual obligation as of December 31, 2024 for our operating lease commitments amounted to RMB45.5 million (US$6.2 million).
Our general and administrative expenses mainly consist of (i) payroll and related expenses for employees engaging in general corporate functions, including the share-based compensation expenses, (ii) professional service fees and other general corporate expenses, including impairment cost, and (iii) expenses associated with the use by these functions of facilities and equipment, such as rental and depreciation expenses.
Our general and administrative expenses mainly consist of (i) payroll and related expenses for employees engaging in general corporate functions, including the share-based compensation expenses, (ii) professional service fees and other general corporate expenses, (iii) impairment loss of intangible assets and allowance for credit losses, and (iv) expenses associated with the use by these functions of facilities and equipment, such as rental and depreciation expenses.
Our restricted cash was RMB667.7 million, RMB517.4 million and RMB577.1 million (US$81.3 million) as of December 31, 2021, 2022 and 2023, respectively. Our restricted cash primarily consists of premiums collected by us from the insurance consumers in a fiduciary capacity until disbursed to the insurance carriers. Restricted cash also includes guarantee deposits.
Our restricted cash was RMB517.4 million, RMB577.1 million and RMB520.6 million (US$71.3 million) as of December 31, 2022, 2023 and 2024, respectively. Our restricted cash primarily consists of premiums collected by us from the insurance consumers in a fiduciary capacity until disbursed to the insurance carriers. Restricted cash also includes guarantee deposits.
As of December 31, 2021, 2022 and 2023, our prepaid expense and other assets were RMB369.8 million, RMB342.5 million and RMB189.8 million (US$26.7 million), respectively. Insurance premium payables represent insurance premiums we collected on behalf of insurance carriers from the insurance consumers but have not yet been remitted to insurance carriers as of the balance sheet dates.
As of December 31, 2022, 2023 and 2024, our prepaid expense and other assets were RMB342.5 million, RMB189.8 million and RMB182.6 million (US$25.0 million), respectively. Insurance premium payables represent insurance premiums we collected on behalf of insurance carriers from the insurance consumers but have not yet been remitted to insurance carriers as of the balance sheet dates.
Our sales and marketing expenses primarily consist of (i) marketing expenses for user acquisition and brand building, (ii) payroll and related expenses for employees involved in sales and marketing functions, and (iii) the associated expenses of facilities and equipment, such as depreciation expenses, rental and others. General and administrative expenses.
Our sales and marketing expenses primarily consist of (i) marketing expenses for user acquisition and brand building, (ii) payroll and related expenses for employees involved in sales and marketing functions, (iii) outsourced sales and marketing service fees to third parties, and (iv) the associated expenses of facilities and equipment, such as depreciation expenses, rental and others. General and administrative expenses.
Operating costs Our operating costs increased by 17.3% from RMB1,019.4 million in 2022 to RMB1,195.5 million (US$168.4 million) in 2023, which was mainly due to (i) an increase of RMB109.3 million (US$15.4 million) in costs of referral and service fees, (ii) an increase of RMB62.0 million (US$8.7 million) in the crowdfunding consultants team costs as we commenced generating crowdfunding service fees since April 2022, and (iii) the consolidation of the financial results of Shenlanbao, which incurred operating costs of RMB38.7 million (US$5.5 million), partially offset by (i) a decrease of RMB19.5 million (US$2.7 million) in the cost of one-year health insurance coverage related to the termination of mutual aid plan based on the final settlement information, which occurred in the third quarter of 2022, and (ii) a decrease of RMB15.1 million (US$2.1 million) in personnel costs.
Operating costs and expenses Our total operating costs and expenses increased by RMB313.7 million, or 13.5%, from RMB2,323.8 million in 2022 to RMB2,637.5 million in 2023, which was mainly due to the consolidation of the financial results of Shenlanbao which generated operating costs and expenses of RMB130.7 million. 113 Table of Contents Operating costs Our operating costs increased by 17.3% from RMB1,019.4 million in 2022 to RMB1,195.5 million in 2023, which was mainly due to (i) an increase of RMB109.3 million in costs of referral and service fees, (ii) an increase of RMB62.0 million in the crowdfunding consultants team costs as we commenced generating crowdfunding service fees since April 2022, and (iii) the consolidation of the financial results of Shenlanbao, which incurred operating costs of RMB38.7 million, partially offset by (i) a decrease of RMB19.5 million in the cost of one-year health insurance coverage related to the termination of mutual aid plan based on the final settlement information, which occurred in the third quarter of 2022, and (iii) a decrease of RMB15.1 million in personnel costs.
In March 2024, our board of directors approved a special cash dividend of US$0.04 per ADS or US$0.004 per ordinary share to shareholders of record as of the close of business on April 19, 2024.
In March 2024, our board of directors approved a special cash dividend of US$0.04 per ADS or US$0.004 per ordinary share to shareholders of record as of the close of business on April 19, 2024. The aggregate payment amounted to approximately US$14.8 million.
B. Liquidity and Capital Resources We had net cash used in operating activities of RMB1,096.7 million in 2021, and net cash provided by operating activities of RMB765.7 million in 2022 and RMB406.5 million (US$57.3 million) in 2023. Our primary sources of liquidity have been proceeds from operating activities and equity and debt financing.
B. Liquidity and Capital Resources We had net cash provided by operating activities of RMB765.7 million in 2022, RMB406.5 million in 2023 and RMB437.3 million (US$59.9 million) in 2024. Our primary sources of liquidity have been proceeds from operating activities and equity and debt financing.
Sales and marketing expenses Our sales and marketing expenses increased by 18.6% from RMB624.5 million in 2022 to RMB740.5 million (US$104.3 million) in 2023, which was mainly due to (i) the consolidation of the financial results of Shenlanbao, which incurred sales and marketing expenses of RMB67.1 million (US$9.5 million), (ii) an increase of RMB100.8 million (US$14.2 million) in marketing expenses to third-party traffic channels, (iii) an increase of RMB29.8 million (US$4.2 million) in personnel costs and share-based compensation costs, partially offset by a decrease of RMB86.3 million (US$12.2 million) in outsourced sales and marketing service fees to third parties. 117 Table of Contents General and administrative expenses Our general and administrative expenses increased by 3.5% from RMB388.7 million in 2022 to RMB402.4 million (US$56.7 million) in 2023, which was mainly due to the consolidation of the financial results of Shenlanbao, which incurred general and administrative expenses of RMB12.9 million (US$1.8 million).
Sales and marketing expenses Our sales and marketing expenses increased by 18.6% from RMB624.5 million in 2022 to RMB740.5 million in 2023, which was mainly due to (i) the consolidation of the financial results of Shenlanbao, which incurred sales and marketing expenses of RMB67.1 million, (ii) an increase of RMB100.8 million in marketing expenses to third-party traffic channels, (iii) an increase of RMB29.8 million in personnel costs and share-based compensation costs, partially offset by a decrease of RMB86.3 million in outsourced sales and marketing service fees to third parties.
Furthermore, we have invested in technology to accumulate and process multi-dimensional consumer data and transaction data, and we plan to conduct in-depth analysis as analysis of consumer needs will contribute to our consumer acquisition and conversion, product design and risk management capabilities, which in turn improves our overall operational margin.
Furthermore, we have invested in technology to accumulate and process multi-dimensional consumer data and transaction data, and have conducted in-depth analysis to improve our user acquisition and conversion, product design and risk management capabilities, which in turn improves our overall operational margin.
Our accrued expenses and other current liabilities were RMB498.8 million, RMB584.1 million and RMB597.7 million (US$84.2 million) as of December 31, 2021, 2022 and 2023, respectively. Although we consolidate the results of the VIEs, we only have access to the assets or earnings of the VIEs through our contractual arrangements with the VIEs and their shareholders. See “Item 4.
Our accrued expenses and other current liabilities were RMB584.1 million, RMB597.7 million and RMB704.0 million (US$96.5 million) as of December 31, 2022, 2023 and 2024, respectively. 116 Table of Contents Although we consolidate the results of the VIEs, we only have access to the assets or earnings of the VIEs through our contractual arrangements with the VIEs and their shareholders.
Risk Factors—Risks Related to Doing Business in China—Regulation in mainland China of loans to and direct investment in the entities in mainland China by offshore holding companies may delay us from using the proceeds of financing activities to make loans or additional capital contributions to our subsidiaries in mainland China and to make loans to the VIEs, which could materially and adversely affect our liquidity and our ability to fund and expand our business.” The following table sets forth the movements of our cash flows for the periods presented: For the Year Ended December 31, 2021 2022 2023 RMB RMB RMB US$ (in thousands) Selected Consolidated Cash Flow Data: Net cash (used in)/provided by operating activities (1,096,652) 765,705 406,516 57,258 Net cash used in investing activities (846,898) (139,819) (1,172,960) (165,208) Net cash provided by/(used in) financing activities 2,119,670 (57,457) (377,238) (53,133) Effect of exchange rate changes on cash and cash equivalents (14,086) 37,723 26,173 3,685 Net increase/(decrease) in cash and cash equivalents and restricted cash 162,034 606,152 (1,117,509) (157,398) Total cash and cash equivalents and restricted cash at beginning of year 1,323,349 1,485,383 2,091,535 294,587 Total cash and cash equivalents and restricted cash at end of year 1,485,383 2,091,535 974,026 137,189 122 Table of Contents Operating activities Net cash provided by operating activities in 2023 was RMB406.5 million (US$57.3 million).
Risk Factors—Risks Related to Doing Business in China—Regulation in mainland China of loans to and direct investment in the entities in mainland China by offshore holding companies may delay us from using the proceeds of financing activities to make loans or additional capital contributions to our subsidiaries in mainland China and to make loans to the VIEs, which could materially and adversely affect our liquidity and our ability to fund and expand our business.” The following table sets forth the movements of our cash flows for the periods presented: For the Year Ended December 31, 2022 2023 2024 RMB RMB RMB US$ (in thousands) Selected Consolidated Cash Flow Data: Net cash provided by operating activities 765,705 406,516 437,250 59,904 Net cash (used in)/provided by investing activities (139,819) (1,172,960) 291,637 39,953 Net cash used in financing activities (57,457) (377,238) (198,579) (27,205) Effect of exchange rate changes on cash and cash equivalents 37,723 26,173 2,577 353 Net increase/(decrease) in cash and cash equivalents and restricted cash 606,152 (1,117,509) 532,885 73,005 Total cash and cash equivalents and restricted cash at beginning of year 1,485,383 2,091,535 974,026 133,441 Total cash and cash equivalents and restricted cash at end of year 2,091,535 974,026 1,506,911 206,446 Operating activities Net cash provided by operating activities in 2024 was RMB437.3 million (US$59.9 million).
Operating costs primarily consists of (i) payroll and related expenses for insurance agents and customer service personnel, (ii) transaction fees charged by third-party payment platforms relating to insurance brokerage services, (iii) costs of referral and service fees, (iv) charges for the usage of the server and cloud service incurred for operational support of the platforms, and the expenses of facilities and equipment, such as depreciation expenses, rental and others, attributed to our principal operations, (v) costs for patient recruitment consultants team, (vi) costs for the crowdfunding consultants team and cost related to the information review and investigation of medical crowdfunding campaigns as we started to generate revenue from crowdfunding service fees since April 2022, and (vii) costs for medical expenses and one-year health insurance coverage we offered related to termination of the Waterdrop Mutual Aid business in March 2021.
Operating costs primarily consists of (i) payroll and related expenses for insurance agents and customer service personnel, (ii) transaction fees charged by third-party payment platforms relating to insurance brokerage services, (iii) costs of referral and service fees, (iv) charges for the usage of the server and cloud service incurred for operational support of the platforms, and the expenses of facilities and equipment, such as depreciation expenses, rental and others, attributed to our principal operations, (v) costs for digital clinical trial solution consultants team, and (vi) costs for the crowdfunding consultants team and cost related to the information review and investigation of medical crowdfunding campaigns.
The increase in accrued expenses and other current liabilities was primarily due to the increase in the accrued customer service expense payable to third-party companies. Net cash used in operating activities in 2021 was RMB1,096.7 million.
The increase in accrued expenses and other current liabilities was primarily due to the increase in the accrued customer service expense payable to third-party companies.
As of December 31, 2023, we had an aggregate of RMB3,970.6 million (US$559.2 million) in cash and cash equivalents, restricted cash and short-term investments, of which approximately 72.1% were held in Renminbi and the remainder was mainly held in U.S. dollars.
As of December 31, 2024, we had an aggregate of RMB4.2 billion (US$574.2 million) in cash and cash equivalents, restricted cash, short-term investments and long-term debt investments included in long-term investments, of which approximately 45.9% were held in Renminbi and the remainder was mainly held in U.S. dollars.
Our research and development expenses as a percentage of net operating revenue increased from 10.4% in 2022 to 11.4% in 2023. 112 Table of Contents Key Components of Results of Operations Operating revenue, net We generate net operating revenue primarily from (i) providing insurance brokerage services to insurance carriers, (ii) providing technical services to insurance carriers and other insurance brokerage or agency companies through our platforms, (iii) crowdfunding service fees from operating Waterdrop Medical Crowdfunding, and (iv) digital clinical trial solution income, mainly deriving from matching qualified and suitable patients for enrollment in clinical trials for biopharmaceutical companies and leading biotechnology companies.
We have promoted technology advances in certain sales and customer service processes that effectively reduced costs, namely our own CRM system and AI applications. 107 Table of Contents Key Components of Results of Operations Operating revenue, net We generate net operating revenue primarily from (i) providing insurance brokerage services to insurance carriers, (ii) providing technical services to insurance carriers and other insurance brokerage or agency companies through our platforms, (iii) crowdfunding service fees from operating Waterdrop Medical Crowdfunding, and (iv) digital clinical trial solution income, mainly deriving from matching qualified and suitable patients for enrollment in clinical trials for biopharmaceutical companies and leading biotechnology companies.
Risk Factors—Risks Related to Our Corporate Structure—Contractual arrangements in relation to the VIEs may be subject to scrutiny by the PRC tax authorities and they may determine that we or the VIEs owe additional taxes, which could negatively affect our financial condition and the value of your investment.” Results of Operations The following table sets forth a summary of our consolidated results of operations for the periods presented, both in absolute amount and as a percentage of our net operating revenue for the periods presented. For the Year Ended December 31, 2021 2022 2023 RMB (%) RMB (%) RMB US$ (%) (in thousands, except for percentage data) Operating revenue, net 3,205,914 100.0 2,801,768 100.0 2,630,707 370,527 100.0 Operating costs and expenses Operating costs (1,054,475) (32.9) (1,019,362) (36.4) (1,195,544) (168,389) (45.5) Sales and marketing expenses (1) (3,104,769) (96.8) (624,478) (22.3) (740,451) (104,290) (28.1) General and administrative expenses (530,522) (16.5) (388,651) (13.9) (402,395) (56,676) (15.3) Research and development expenses (378,990) (11.8) (291,290) (10.3) (299,060) (42,122) (11.4) Total operating costs and expenses: (5,068,756) (158.0) (2,323,781) (82.9) (2,637,450) (371,477) (100.3) Operating (loss)/profit (1,862,842) (58.0) 477,987 17.1 (6,743) (950) (0.3) Other income Interest income 48,662 1.5 81,713 2.9 136,043 19,161 5.2 Foreign currency exchange gain 9,349 0.3 4,064 0.1 4,342 612 0.2 Others, net 9,764 0.3 66,929 2.4 30,598 4,310 1.1 (Loss)/profit before income tax (1,795,067) (55.9) 630,693 22.5 164,240 23,133 6.2 Income tax benefit/(expense) 220,987 6.9 (22,976) (0.8) (555) (78) (0.0) Net (loss)/profit (1,574,080) (49.0) 607,717 21.7 163,685 23,055 6.2 Note: (1) The breakdown of sales and marketing expenses is as follows: For the Year Ended December 31, 2021 2022 2023 RMB RMB RMB US$ (in thousands) Marketing expenses for user acquisition and brand building 2,232,942 120,471 240,351 33,853 Payroll and related expenses for employees 295,434 316,795 390,534 55,006 Expenses of facilities and equipment 21,023 22,133 21,627 3,046 Outsourced sales and marketing service fee to third parties 507,421 149,249 63,512 8,945 Others 47,949 15,830 24,427 3,440 Total sales and marketing expenses 3,104,769 624,478 740,451 104,290 116 Table of Contents Year Ended December 31, 2023 Compared to Year Ended December 31, 2022 Operating revenue, net Our net operating revenue decreased by 6.1% from RMB2,801.8 million in 2022 to RMB2,630.7 million (US$370.5 million) in 2023, including the revenue generated by Shenlanbao of RMB92.9 million (US$13.1 million) after consolidation.
Risk Factors—Risks Related to Our Corporate Structure—Contractual arrangements in relation to the VIEs may be subject to scrutiny by the PRC tax authorities and they may determine that we or the VIEs owe additional taxes, which could negatively affect our financial condition and the value of your investment.” Results of Operations The following table sets forth a summary of our consolidated results of operations for the periods presented, both in absolute amount and as a percentage of our net operating revenue for the periods presented. For the Year Ended December 31, 2022 2023 2024 RMB (%) RMB (%) RMB US$ (%) (in thousands, except for percentage data) Operating revenue, net 2,801,768 100.0 2,630,707 100.0 2,771,821 379,738 100.0 Operating costs and expenses Operating costs (1,019,362) (36.4) (1,195,544) (45.5) (1,314,740) (180,119) (47.4) Sales and marketing expenses (1) (624,478) (22.3) (740,451) (28.1) (694,769) (95,183) (25.1) General and administrative expenses (388,651) (13.9) (402,395) (15.3) (367,652) (50,368) (13.3) Research and development expenses (291,290) (10.3) (299,060) (11.4) (216,502) (29,661) (7.8) Total operating costs and expenses: (2,323,781) (82.9) (2,637,450) (100.3) (2,593,663) (355,331) (93.6) Operating profit/(loss) 477,987 17.1 (6,743) (0.3) 178,158 24,407 6.4 Other income Interest income 81,713 2.9 136,043 5.2 149,121 20,429 5.4 Foreign currency exchange gain 4,064 0.1 4,342 0.2 8,016 1,098 0.3 Others, net 66,929 2.4 30,598 1.1 25,295 3,465 0.9 Profit before income tax 630,693 22.5 164,240 6.2 360,590 49,399 13.0 Income tax expense (22,976) (0.8) (555) (0.0) (9,707) (1,330) (0.3) Net profit 607,717 21.7 163,685 6.2 350,883 48,069 12.7 Note: (1) The breakdown of sales and marketing expenses is as follows: For the Year Ended December 31, 2022 2023 2024 RMB RMB RMB US$ (in thousands) Marketing expenses for user acquisition and brand building 120,471 240,351 280,906 38,484 Payroll and related expenses for employees 316,795 390,534 297,451 40,751 Expenses of facilities and equipment 22,133 21,627 20,293 2,780 Outsourced sales and marketing service fee to third parties 149,249 63,512 75,994 10,411 Others 15,830 24,427 20,125 2,757 Total sales and marketing expenses 624,478 740,451 694,769 95,183 111 Table of Contents Year Ended December 31, 2024 Compared to Year Ended December 31, 2023 Operating revenue, net Our net operating revenue increased by 5.4% from RMB2,630.7 million in 2023 to RMB2,771.8 million (US$379.7 million) in 2024.
Other revenues mainly include income generated from digital clinical trial solution and other new initiatives. We derive digital clinical trial solution income primarily from matching qualified and suitable patients for enrollment in clinical trials for our customers that mainly include biopharmaceutical companies and leading biotechnology companies.
We derive digital clinical trial solution income primarily from matching qualified and suitable patients for enrollment in clinical trials for our customers that mainly include biopharmaceutical companies and leading biotechnology companies. We enter into patient recruitment contracts with these customers to match qualified patients with optimal suitability for enrollment in clinical trials.
The following table sets forth the breakdown of our total operating costs and expenses, in amounts and as percentages of net operating revenue for each of the years presented: For the Year Ended December 31, 2021 2022 2023 RMB (%) RMB (%) RMB US$ (%) (in thousands, except for percentage data) Operating costs and expenses: Operating costs 1,054,475 32.9 1,019,362 36.4 1,195,544 168,389 45.5 Sales and marketing expenses 3,104,769 96.8 624,478 22.3 740,451 104,290 28.1 General and administrative expenses 530,522 16.5 388,651 13.9 402,395 56,676 15.3 Research and development expenses 378,990 11.8 291,290 10.3 299,060 42,122 11.4 Total operating costs and expenses: 5,068,756 158.0 2,323,781 82.9 2,637,450 371,477 100.3 Operating costs.
The following table sets forth the breakdown of our total operating costs and expenses, in amounts and as percentages of net operating revenue for each of the years presented: For the Year Ended December 31, 2022 2023 2024 RMB (%) RMB (%) RMB US$ (%) (in thousands, except for percentage data) Operating costs and expenses: Operating costs 1,019,362 36.4 1,195,544 45.5 1,314,740 180,119 47.4 Sales and marketing expenses 624,478 22.3 740,451 28.1 694,769 95,183 25.1 General and administrative expenses 388,651 13.9 402,395 15.3 367,652 50,368 13.3 Research and development expenses 291,290 10.3 299,060 11.4 216,502 29,661 7.8 Total operating costs and expenses: 2,323,781 82.9 2,637,450 100.3 2,593,663 355,331 93.6 Operating costs.
The following table sets forth the breakdown of our operating revenue by segment, in amounts and as percentages of operating revenue for the years presented: For the Year Ended December 31, 2021 2022 2023 RMB (%) RMB (%) RMB US$ (%) (in thousands, except for percentage data) Segment revenue: Insurance (1) Brokerage income -Short-term insurance brokerage income 2,037,677 63.6 1,628,902 58.1 1,381,855 194,630 52.5 -Long-term insurance brokerage income 789,790 24.6 714,426 25.5 823,305 115,960 31.3 Brokerage income subtotal 2,827,467 88.2 2,343,328 83.6 2,205,160 310,590 83.8 Technical service income 243,542 7.6 215,832 7.7 135,755 19,121 5.2 Insurance total 3,071,009 95.8 2,559,160 91.3 2,340,915 329,711 89.0 Crowdfunding — — 155,803 5.6 162,683 22,913 6.2 Others 134,905 4.2 86,805 3.1 127,109 17,903 4.8 Total 3,205,914 100.0 2,801,768 100.0 2,630,707 370,527 100.0 Note: (1) We started to consolidate the financial results of Shenlanbao since July 4, 2023 and reported the results of Shenlanbao under the Insurance segment.
The following table sets forth the breakdown of our operating revenue, in amounts and as percentages of operating revenue by segment for the years presented: For the Year Ended December 31, 2022 2023 2024 RMB (%) RMB (%) RMB US$ (%) (in thousands, except for percentage data) Segment revenue: Insurance (1) Brokerage income -Short-term insurance brokerage income 1,628,902 58.1 1,381,855 52.5 1,309,432 179,392 47.2 -Long-term insurance brokerage income 714,426 25.5 823,305 31.3 1,013,406 138,836 36.6 Brokerage income subtotal 2,343,328 83.6 2,205,160 83.8 2,322,838 318,228 83.8 Technical service income 215,832 7.7 135,755 5.2 40,939 5,608 1.5 Insurance total 2,559,160 91.3 2,340,915 89.0 2,363,777 323,836 85.3 Crowdfunding 155,803 5.6 162,683 6.2 267,650 36,668 9.6 Others 86,805 3.1 127,109 4.8 140,394 19,234 5.1 Total 2,801,768 100.0 2,630,707 100.0 2,771,821 379,738 100.0 Note: (1) We started to consolidate the financial results of Shenlanbao since July 4, 2023 and reported the results of Shenlanbao under the Insurance segment.
Interest income Our interest income increased by 66.5% from RMB81.7 million in 2022 to RMB136.0 million (US$19.2 million) in 2023. The increase was mainly due to the increase in interest rate.
Interest income Our interest income increased by 66.5% from RMB81.7 million in 2022 to RMB136.0 million in 2023. The increase was mainly due to the increase in interest rate. Net profit As a result of the foregoing, our net profit for the year of 2023 was RMB163.7 million, compared to RMB607.7 million for the year of 2022.
Net cash used in investing activities in 2021 was RMB846.9 million, consisting primarily of net cash used in purchase of short-term investment products, and cash paid for purchase of property, equipment and software. 123 Table of Contents Financing activities Net cash used in financing activities in 2023 was RMB377.2 million (US$53.1 million), consisting primarily of payment in connection with the share repurchase program, partially offset by the proceeds from short-term loans.
Net cash used in financing activities in 2023 was RMB377.2 million, consisting primarily of payment in connection with the share repurchase program, partially offset by the proceeds from short-term loans.
As of December 31, 2021, 2022 and 2023, our insurance premium payables were RMB685.0 million, RMB516.7 million and RMB592.0 million (US$83.4 million), respectively. 121 Table of Contents Our accrued expenses and other current liabilities represent primarily (i) accrued marketing and selling expenses, (ii) payroll and welfare payable, and (iii) payable related to medical crowdfunding business, which mainly represents the funds we collected through the third-party payment platforms that has not been transferred to custodian bank.
Our accrued expenses and other current liabilities represent primarily (i) accrued marketing and customer service expenses, (ii) payroll and welfare payable, and (iii) payable related to medical crowdfunding business, which mainly represents the funds we collected through the third-party payment platforms that has not been transferred to custodian bank.
In addition to the growth in the FYP per policy, the number of policies per consumer remained relatively stable at 1.7 and 1.6 in 2022 and 2023, respectively.
Overall, the FYP per policy rose from RMB803 in 2023 to RMB1,047 in 2024. In addition to this growth, the number of policies per consumer remained stable at 1.6 in 2023 and 1.5 in 2024.
Our large consumer base and strong business development capabilities allow us to negotiate favorable terms in our business cooperation with insurance carriers. We need to keep the growth of our business, brand influence, value-added technology service capabilities and risk management capabilities so as to strengthen and deepen the cooperation with our existing insurance carriers.
We need to keep the growth of our business, brand influence, value-added technology service capabilities and risk management capabilities so as to strengthen and deepen the cooperation with our existing insurance carriers. Operating efficiency and leverage We have incurred significant costs and expenses in building our platform, growing our consumer base and developing capabilities in data analysis and technology.
Income tax benefit/(expense) Income tax expense in 2022 was RMB23.0 million, compared with income tax benefit of RMB221.0 million in 2021. The difference was primarily due to the net operating profit generated in 2022. 119 Table of Contents Critical Accounting Estimates We prepare our financial statements in accordance with U.S.
Income tax expense Income tax expense in 2023 was RMB0.6 million, compared with RMB23.0 million in 2022. The decrease was primarily due to the decrease of profit before tax. 114 Table of Contents Critical Accounting Estimates We prepare our financial statements in accordance with U.S. GAAP, which requires our management to make judgments, estimates and assumptions.
The aggregate payment will amount to approximately US$15 million. We believe our cash on hand will be sufficient to meet our current and anticipated needs for working capital and capital expenditure requirement for at least the next 12 months.
The payment date is expected to be on or around April 30, 2025 for holders of ordinary shares and on or around May 2, 2025 for holders of ADSs. We believe our cash on hand will be sufficient to meet our current and anticipated needs for working capital and capital expenditure requirement for at least the next 12 months.
The long-term health and life insurance products accounted for 28.8% and 31.3% of the FYP generated through us in 2022 and 2023, respectively. The FYP per policy of long-term health and life insurance products increased from RMB5,004 in 2022 to RMB7,180 in 2023. As a result, the FYP per policy increased from RMB711 in 2022 to RMB803 in 2023.
The acquisition of Shenlanbao in 2023 further enhanced our service capabilities. Long-term health and life insurance products accounted for 31.3% and 30.4% of the FYP generated through our platforms in 2023 and 2024, respectively. The FYP per policy for long-term health and life insurance products increased from RMB7,180 in 2023 to RMB7,969 in 2024.
Cooperation with insurance carriers We cooperate with insurance carriers to offer their standard insurance products or to design and develop tailor-made insurance products, and our relationship with insurance carriers is crucial to our success. As of December 31, 2023, we had established business cooperation with 101 insurance carriers.
Consequently, the FYP per consumer increased from RMB1,324 in 2023 to RMB1,594 in 2024. 106 Table of Contents Cooperation with insurance carriers We cooperate with insurance carriers to offer their standard insurance products or to design and develop tailor-made insurance products, and our relationship with insurance carriers is crucial to our success.
Operating costs and expenses Our total operating costs and expenses increased by RMB313.7 million, or 13.5%, from RMB2,323.8 million in 2022 to RMB2,637.5 million (US$371.5 million) in 2023, which was mainly due to the consolidation of the financial results of Shenlanbao which generated operating costs and expenses of RMB130.7 million.
Operating costs and expenses Our total operating costs and expenses decreased by RMB43.8 million, or 1.7%, from RMB2,637.5 million in 2023 to RMB2,593.7 million (US$355.3 million) in 2024, which was mainly due to the effective cost control measures.
Net cash used in financing activities in 2022 was RMB57.5 million (US$8.3 million), consisting primarily of the payment in connection with the share repurchase program. Net cash provided by financing activities in 2021 was RMB2,119.7 million, consisting primarily of net proceeds from our IPO, partially offset by the payment of share repurchase program.
Financing activities Net cash used in financing activities in 2024 was RMB198.6 million (US$27.2 million), consisting primarily of payment in connection with the share repurchase program, and payment of dividend to shareholders, partially offset by the net proceeds from short-term loans.
We currently organize and report our business in three operating segments: (i) insurance, which mainly includes Waterdrop Insurance Marketplace, Shenlanbao Insurance Marketplace and technical support service; (ii) crowdfunding, which mainly includes Waterdrop Medical Crowdfunding; and (iii) others, which mainly include digital clinical trial solution and other new initiatives.
We currently organize and report our business in the following segments: (i) insurance, which mainly includes Waterdrop Insurance Marketplace, Shenlanbao Insurance Marketplace and technical support service; (ii) crowdfunding, which mainly includes Waterdrop Medical Crowdfunding, and (iii) others, which do not individually or in the aggregate meet the quantitative and qualitative thresholds to be individually reportable and are aggregated.
Net profit As a result of the foregoing, our net profit for the year of 2023 was RMB163.7 million (US$23.1 million), compared to RMB607.7 million for the year of 2022. Income tax expense Income tax expense in 2023 was RMB0.6 million (US$0.1 million), compared with RMB23.0 million in 2022.
Interest income Our interest income increased by 9.6% from RMB136.0 million in 2023 to RMB149.1 million (US$20.4 million) in 2024 due to the increased proportion of long-term debt investments. Net profit As a result of the foregoing, our net profit for the year of 2024 was RMB350.9 million (US$48.1 million), compared to RMB163.7 million for the year of 2023.
We enter into patient recruitment contracts with these customers to match qualified patients with optimal suitability for enrollment in clinical trials. We typically charge a fixed unit price per successful match. Other new initiatives are those early-stage businesses. Revenues generated from the other new initiatives are not material, either individually or in aggregate.
We typically charge a fixed unit price per successful match. Other new initiatives are those early-stage businesses. Revenues generated from the other new initiatives are not material, either individually or in aggregate. For details of the segment information, see Note 12 “Segment Information” to our audited consolidated financial statements included elsewhere in this annual report.
As of December 31, 2021, 2022 and 2023, our contract assets were RMB593.5 million, RMB553.7 million and RMB707.3 million (US$99.6 million), respectively.
As of December 31, 2022, 2023 and 2024, our insurance premium payables were RMB516.7 million, RMB592.0 million and RMB537.3 million (US$73.6 million), respectively.
The platform service fee is charged at a certain percentage of the withdrawal amount for a single crowdfunding campaign, subject to a capped maximum amount for a single crowdfunding campaign. The service fee is payable to us only upon the successful withdrawal of the funds by the patient. 113 Table of Contents Others.
Crowdfunding services primarily consist of providing technical and internet support, managing and reviewing the crowdfunding campaigns, and facilitating the collection and transfer of funds to the patients. The platform service fee is charged at a certain percentage of the withdrawal amount for a single crowdfunding campaign, subject to a capped maximum amount for a single crowdfunding campaign.
Material cash requirements Our material cash requirements as of December 31, 2023 and any subsequent interim period primarily include our capital expenditures and operating lease commitments. Our capital expenditures primarily represent cash paid for purchase of property, equipment and software. We made capital expenditures of RMB35.7 million, RMB11.9 million and RMB13.5 million (US$1.9 million) in 2021, 2022 and 2023, respectively.
Our capital expenditures primarily represent cash paid for purchase of property, equipment and software. We made capital expenditures of RMB11.9 million, RMB13.5 million and RMB218.4 million (US$29.9 million) in 2022, 2023 and 2024, respectively. The increased expenditures in 2024 were mainly due to the purchase of a commercial real estate property in Beijing for business operations.
Year Ended December 31, 2022 Compared to Year Ended December 31, 2021 Operating revenue, net Our net operating revenue decreased by 12.6% from RMB3,205.9 million for 2021 to RMB2,801.8 million in 2022, which was primarily due to the decrease in net operating revenue from insurance income, partially offset by the increase in net operating revenue from crowdfunding income and other income.
Year Ended December 31, 2023 Compared to Year Ended December 31, 2022 Operating revenue, net Our net operating revenue decreased by 6.1% from RMB2,801.8 million in 2022 to RMB2,630.7 million in 2023, including the revenue generated by Shenlanbao of RMB92.9 million after consolidation.
We pay guarantee deposits required by National Financial Regulatory Administration in order to protect insurance premium appropriation by insurance broker and agency. Furthermore, a guarantee deposit for foreign exchange settlement was paid in 2020 to a commercial bank in order to carry out foreign exchange settlement.
We pay guarantee deposits required by National Financial Regulatory Administration in order to protect insurance premium appropriation by insurance broker and agency. Our accounts receivable represents primarily brokerage commission fee receivable from insurance carriers and technical service fees receivable from insurance carriers.
Our contract assets are recorded for arrangements when we have provided the insurance brokerage services but for which the related commission payments are not yet due. Contract assets represent primarily the brokerage commission fee that is contingent upon the future premium payment of the insurance policy holders and retention-based bonus.
As of December 31, 2022, 2023 and 2024, our accounts receivable was RMB675.8 million, RMB693.1 million and RMB716.2 million (US$98.1 million), respectively. Our contract assets are recorded for arrangements when we have provided the insurance brokerage services but for which the related commission payments are not yet due.
We began to offer long-term health and life insurance products at the end of 2018, and we have been endeavoring to raise consumer awareness, and demonstrate the value and importance of long-term health and life insurance through our interactions with them. The acquisition of Shenlanbao in 2023 also significantly expanded our product offerings and service capabilities.
As a result of increasing product and user diversity, the FYP per policy for short-term health insurance products rose from RMB572 in 2023 to RMB759 in 2024. Since introducing long-term health and life insurance products at the end of 2018, we have actively worked to raise consumer awareness and demonstrate the value of these products through our platform and service.
General and administrative expenses Our general and administrative expenses decreased by 26.7% from RMB530.5 million in 2021 to RMB388.7 million in 2022, which was mainly due to (i) a decrease of RMB109.8 million in share-based compensation expenses, (ii) a RMB21.2 million decrease in personnel cost, both of which were as a result of our cost control measures, and (iii) a decrease of RMB39.0 million impairment loss over prepayment for the year of 2021, and partially offset by an increase of RMB23.5 million allowance for doubtful accounts for the year of 2022.
General and administrative expenses Our general and administrative expenses decreased by 8.6% from RMB402.4 million in 2023 to RMB367.7 million (US$50.4 million) in 2024, which was mainly due to (i) a decrease of RMB32.5 million in the professional service fee, (ii) a decrease of RMB18.3 million in general and administrative personnel costs and share-based compensation expenses, (iii) a decrease of RMB5.9 million in office rental and office administrative expenses, partially offset by (iv) a non-cash impairment of intangible assets related to Shenlanbao of RMB20.6 million recorded in 2024, and (v) an increase of RMB9.6 million in allowance for credit losses.
Sales and marketing expenses Our sales and marketing expenses decreased by 79.9% from RMB3,104.8 million in 2021 to RMB624.5 million in 2022, which was mainly due to (i) RMB2,112.5 million decrease in marketing expenses to third-party traffic channels as part of our cost control measures, and (ii) RMB358.2 million decrease in outsourced sales and marketing service fee to third parties.
Sales and marketing expenses Our sales and marketing expenses decreased by 6.2% from RMB740.5 million in 2023 to RMB694.8 million (US$95.2 million) in 2024, which was primarily due to (i) a decrease of RMB93.1 million in personnel costs and share based compensation costs, partially offset by (ii) an increase of RMB40.6 million in marketing expenses to third-party traffic channel, and (iii) an increase of RMB12.5 million in outsourced sales and marketing service fees to third parties.
For details of the segment information, see Note 12 “Segment Information” to our audited consolidated financial statements included elsewhere in this annual report. Operating costs and expenses Our operating costs and expenses consist of operating costs, sales and marketing expenses, general and administrative expenses, research and development expenses.
Operating costs and expenses Our operating costs and expenses consist of operating costs, sales and marketing expenses, general and administrative expenses, research and development expenses.
First year premium per consumer As the consumers’ awareness for health protection and insurance products in China were still substantially lower than in developed countries, many insurance consumers on our platform start with purchases of short-term products. The FYP per policy of short-term health insurance products generated through us grew from RMB528 in 2022 to RMB572 in 2023.
As of December 31, 2024, we cumulatively offered 1,967 insurance products on Waterdrop Insurance Marketplace, as compared with 1,357 as of December 31, 2023. In China, consumer awareness of health protection and insurance products remains significantly lower than in developed countries, leading many users on our platform to initially purchase short-term products.
The difference between the net loss of RMB1,574.1 million and negative operating cash flow of RMB1,096.7 million was the result of additional cash of RMB191.9 million generated due to changes in working capital accounts, and adding back non-cash expenses items such as share-based compensation expenses of RMB226.2 million, and depreciation of property, equipment and software of RMB17.9 million.
The difference between the net profit of RMB350.9 million (US$48.1 million) and positive operating cash flow of RMB437.3 million was non-cash expenses items such as share-based compensation expense of RMB86.9 million, and depreciation of property, equipment and software of RMB11.4 million, and changes in working capital accounts, which mainly include (i) RMB66.2 million increase in contract assets, (ii) RMB54.6 million decrease in insurance premium payables, and (iii) RMB35.1 million increase in accounts receivable, partially offset by RMB107.9 million increase in accrued expenses and other current liabilities. 117 Table of Contents Specifically, the decrease in insurance premium payables was primarily due to the decrease of turnover days.